ClinicalTrials.gg
CompletedNCT03333330IMPLACUpdated Feb 19, 2018

IMaging Della PLAcca Carotidea

A Phase 3 interventional study of Visipaque 320 and SonoVue in Carotid Artery Plaque, Atherosclerosis and Ischemic Stroke, sponsored by Enrico Ammirati. Completed. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2018-02-19.

Sponsored by Enrico Ammirati · Phase 3, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 5 years 6 months after the study started (first participant enrolled Apr 2012, registered Oct 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
75
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Background-White matter hyperintensities (WMH), patchy areas of hyperintense signal on T2-weighted or Fluid Attenuated Inversion Recovery sequences on brain magnetic resonance imaging (MRI), are believed to reflect cerebral burden of ischemic damage and are associated to incident stroke, dementia and eventually mortality in otherwise healthy subjects. Also brain atrophy has been related with presence of carotid atherosclerosis and vascular cognitive impairment. Carotid atherosclerosis may contribute to the genesis of WMH. A recent meta-analysis by our group comprising 5306 subjects was able to demonstrate an association between the presence of carotid atherosclerosis and WMH (odds ratio, OR, 1.42, 95% confidence interval [CI] 1.22-1.66).

Objective-To evaluate the relation between carotid artery plaque characteristics, cardiovascular risk factors and brain atrophy/WMH burden analyzed quantitatively as number and volume of lesions and as brain volumes, and progression over 18 months of follow up in subjects asymptomatic for cerebrovascular disease with a carotid artery stenosis \<70%.

Read the detailed description
  • Ischemic stroke and vascular cognitive impairment pose a massive clinical, social and economic burden. Disruption of carotid plaques, often non-obstructive, with subsequent thrombosis and distal embolization is one of leading pathogenetic mechanism of ischemic stroke. The widespread use of brain magnetic resonance imaging (MRI) has enabled an increased recognition, especially in elderly subjects, of cerebral alterations in apparently healthy individuals.
  • Carotid plaque may be causative in the development of white matter hyperintensities (WMH, patchy areas of signal hyperintensity on T2-weighted and/or fluid attenuated inversion recovery -FLAIR- sequences), silent brain infarcts (SBI) and eventually brain atrophy.
  • The hypothesis of the investigators is that carotid plaques with features of vulnerability detected by multimodality imaging (including standard ultrasound, contrast enhanced ultrasound -CEUS-, contrast enhanced CT angiography) and larger extent of atherosclerotic process, even if determining only an intermediate degree of stenosis, could bear a more rapid progression of silent WMH and brain atrophy.
  • Carotid CT and CEUS allow fast and reproducible evaluation of plaque size and morphology, alongside with functional parameters. Plaque density and positive remodelling on CT have been repeatedly associated to histological features of plaque vulnerability. At the same time, when compared to standard duplex evaluation, CEUS allowed a better imaging definition of plaque margins and extension, and to evaluate intraplaque neovascularization. The latter associates with local inflammation and plaque vulnerability, and might give rise to plaque hematomas, which are among the substrates for lesion progression and for the development of atherothrombosis.
  • In the initial phase of the study also hybrid imaging with positron tomography and computed tomography angiography (PET/CTA) using 11C-PK11195 was used to detect and quantify intraplaque inflammation in humans.(7) C-PK11195 is a selective ligand for translocator protein, 18kDa (TSPO), which is highly expressed on the surface of activated monocytes/macrophages. This part of the study was prematurely stopped due to problems with the production of the radiotracer with 11[C] (only 13 patients were studied with this approach).

Primary endpoints:

  • The primary endpoint is to identify independent predictors (plaque-related or patient-related) with the progression of WMH through multivariable logistic regression analysis.

Progression of WMH was considered as dichotomous variable: progression versus no progression of WMH.

  • The co-primary end-point is to identify independent predictors (plaque-related or patient-related) with the progression of gray matter (GM)/all brain atrophy through multivariable logistic regression analysis. Progression of brain atrophy was considered as dichotomous variable: progression versus no progression of GM/all brain atrophy.

Statistical considerations:

The investigators calculated the sample size for multivariate logistic regression analysis with a power of 0.8 and an alpha of 0.05. The investigators will analyze the highest tertile of carotid plaques burden in terms of plaque volume versus others (see Sillesen, 2012). By definition, the prevalence of high burden atherosclerosis will be 33%. The investigators estimated a clinically relevant probability of progressing in terms of WMH in the high burden group to be 50%, while subjects without high burden plaques are estimated to progress in terms of WMH as the general population with carotid atherosclerosis in a similar time frame. This probability would be estimated to be around 15% (see Dufoil, 2005 and Pico, 2002). The estimated sample size would be 58 individuals.

02

Conditions studied

  • Carotid Artery Plaque
  • Atherosclerosis
  • Ischemic Stroke

Keywords

  • Carotid atherosclerosis
  • Carotid plaque
  • Brain magnetic resonance imaging
  • Contrast enhanced ultrasound
  • Carotid CT angiography
  • Silent brain ischemia
  • Vascular cognitive impairment
03

In context

Carotid Stenosis

368 studies on the registry are indexed under Carotid Stenosis; 87 are open to participants now.

This study's enrollment of 75 is below the median of 102 across 192 interventional studies indexed under Carotid Stenosis.

Browse Carotid Stenosis studies →

Lead sponsor

This is the only study on the registry with Enrico Ammirati as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • bearing an asymptomatic carotid stenosis of 30-70% in diameter, as established by Doppler-measured peak systolic flow velocity, according to the Society of Radiologists in Ultrasound Consensus Conference (Grant et al. Radiology 2003).

Exclusion criteria

Exclusion Criteria:

  • pregnancy or possibility of pregnancy,
  • history of allergic diathesis,
  • history of stroke or transitory ischemic attack,
  • previous carotid artery stenting or carotid endarterectomy,
  • history of vasculitis,
  • History of drug abuse, alcohol abuse or any psychiatric or social condition which may contraindicate the participation to a clinical study
  • of less than 18 months due to underlying medical conditions,
  • presence of cognitive impairment preventing the patient from providing ,
  • Atrial fibrillation or previous cardiac surgery or positioning of intracardiac devices (excluded coronary stents) as potential confounding causes of cerebral ischemic damage,
  • Known patent foramen ovale (PFO) necessitating anti- treatment
  • Current anti-coagulation,
  • Previous infections to the central nervous system (CNS)
  • Previous surgery to the CNS
  • History of anoxic damage to the CNS
  • Dementia
  • to computed tomography angiography (CTA, estimated \<60 mL/min; history of allergic reaction to iodinated contrast media),
  • Specific contraindication to MRI:

    • Claustrophobia
    • Sickle cell anemia
    • Systemic mastocytosis
    • Implanted cardiac devices (i.e. pacemakers, implantable cardioverter defibrillators)
    • Vascular clips
    • Vertebral distractors
    • Infusion pumps
    • Neurostimulators
    • Liquor derivations
    • Any device which could be dispositioned in the presence of a strong magnetic field
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    Carotid imaging with Visipaque 320 and SonoVue

    Patients undergo to brain MRI, carotid contrast-enhanced CTA, duplex ultrasound, CEUS, blood sampling, clinical structured interview. Intervention is related to the administration of contrast agents: Visipaque 320 for contrast-enhanced CTA, and SonoVue for CEUS

    Drug: Visipaque 320 and SonoVue

Interventions

  • DrugVisipaque 320 and SonoVue

    Drug pages: IodixanolStudies of IodixanolIodixanol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Contrast agent BR1Studies of Contrast agent BR1Contrast agent BR1 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intervention is related to the administration of contrast agents: Iodixanol, 320 mg of iodine per millilitre, Visipaque 320 (GE Healthcare, Milwaukee, WI, USA) for contrast-enahnced CTA, Sodium hexafluoride (SonoVue, Bracco Imaging, Milan, Italy) for CEUS

    Also known as: Contrast agents

06

What researchers measure

Primary outcomes

  1. Changes of total cerebral white matter lesions from baseline (T2-weight lesions, in terms of number and total volumes indexed to the total brain volume)

    We expect that asymptomatic patients with carotid atherosclerosis with characteristics of vulnerability of the plaque can develop a larger burden of silent cerebral ischemic lesions along the timeframe of the study. We are going to compare patients with progression compared those without significant progression or no progression.

    Time frame: 18 months

Secondary outcomes

  1. Changes of total brain volume and grey matter volume from baseline

    We expect that asymptomatic patients with carotid atherosclerosis with characteristics of vulnerability of the plaque can develop atrophy of the total brain volume or/and grey matter volume along the timeframe of the study. We are going to compare patients with progression of atrophy compared those without significant progression or no progression.

    Time frame: 18 months

  2. Changes of ipsilateral cerebral white matter lesions from baseline (T2-weight lesions, in terms of number and total volumes indexed to the total brain volume)

    We expect that asymptomatic patients with carotid atherosclerosis with characteristics of vulnerability of the plaque can develop a larger burden of silent cerebral ischemic lesions along the timeframe of the study. We are going to compare patients with progression compared those without significant progression or no progression.

    Time frame: 18 months

  3. Changes of the carotid total plaque area and extent of CEUS positive plaques

    We expect that asymptomatic patients with carotid atherosclerosis with characteristics of vulnerability of the plaque based on CEUS positive plaques and based on cardiovascular risk factors and ongoing treatments can develop a larger extent of total plaque area or/and extent of CEUS positive plaque.

    Time frame: 18 months

  4. Compare the esteem of the degree and the characteristics of the main plaque with standard Duplex scan versus CEUS using contrast enhanced carotid CT scan as gold standard

    We expect that CEUS can be superior compared with standard Duplax scan of the carotid artery in the evaluation of degree of stenosis and presence of irregularity on the surface of the plaque.

    Time frame: at baseline

Other outcomes

  1. Specific biomarkers (specific T-cell subsets and monocytic subsets and other cytokines) can be associated with WMH and brain atrophy at base line and at follow up (biomarkers to identify progression of WMHs and brain atrophy)

    We expect in particular that circulating HLA-DR+CD4+T cells and CD14+CD16- monocytes will be increased in patients with WMH and/or brain atrophy progression

    Time frame: 18 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Ammirati E, Moroni F, Magnoni M, Rocca MA, Messina R, Anzalone N, De Filippis C, Scotti I, Besana F, Spagnolo P, Rimoldi OE, Chiesa R, Falini A, Filippi M, Camici PG. Relation between characteristics of carotid atherosclerotic plaques and brain white matter hyperintensities in asymptomatic patients. Sci Rep. 2017 Sep 5;7(1):10559. doi: 10.1038/s41598-017-11216-x. PubMed 28874779 ↗
  • Ammirati E, Moroni F, Magnoni M, Di Terlizzi S, Villa C, Sizzano F, Palini A, Garlaschelli K, Tripiciano F, Scotti I, Catapano AL, Manfredi AA, Norata GD, Camici PG. Circulating CD14+ and CD14highCD16- classical monocytes are reduced in patients with signs of plaque neovascularization in the carotid artery. Atherosclerosis. 2016 Dec;255:171-178. doi: 10.1016/j.atherosclerosis.2016.10.004. Epub 2016 Oct 6. PubMed 27751505 ↗
  • Ammirati E, Magnoni M, Moroni F, Di Terlizzi S, Scotti I, Villa C, Sizzano F, Impellizzeri M, Fanelli G, Esposito G, Chiesa R, Camici PG. Reduction of Circulating HLA-DR+ T Cell Levels Correlates With Increased Carotid Intraplaque Neovascularization and Atherosclerotic Burden. JACC Cardiovasc Imaging. 2016 Oct;9(10):1231-1233. doi: 10.1016/j.jcmg.2015.10.010. Epub 2016 Jan 6. No abstract available. PubMed 26777226 ↗
  • Moroni F, Magnoni M, Vergani V, Ammirati E, Camici PG. Fractal analysis of plaque border, a novel method for the quantification of atherosclerotic plaque contour irregularity, is associated with pro-atherogenic plasma lipid profile in subjects with non-obstructive carotid stenoses. PLoS One. 2018 Feb 12;13(2):e0192600. doi: 10.1371/journal.pone.0192600. eCollection 2018. PubMed 29432486 ↗
  • Ammirati E, Moroni F, Magnoni M, Rocca MA, Anzalone N, Cacciaguerra L, Di Terlizzi S, Villa C, Sizzano F, Palini A, Scotti I, Besana F, Spagnolo P, Rimoldi OE, Chiesa R, Falini A, Filippi M, Camici PG. Progression of brain white matter hyperintensities in asymptomatic patients with carotid atherosclerotic plaques and no indication for revascularization. Atherosclerosis. 2019 Aug;287:171-178. doi: 10.1016/j.atherosclerosis.2019.04.230. Epub 2019 May 6. PubMed 31101367 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2012 to primary completion in Oct 2017, 66 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2017
First posted
Nov 6, 2017
StartActual
Apr 2012
Primary completionActual
Oct 2017
CompletionActual
Oct 2017
Last update
Feb 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03333330
Lead sponsor
Enrico Ammirati
Responsible party
Enrico Ammirati (Principal Investigator of the grant number GR-2009-1608780 funded by the Italian Ministry of Health Grant, Università Vita-Salute San Raffaele) — Sponsor-investigator
First posted
Nov 6, 2017
Start date
Apr 2012
Primary completion
Oct 2017
Completion
Oct 2017
Last update
Feb 19, 2018

Study contacts

Enrico Ammirati, Doctor
principal investigator · ASST Grande Ospedale Metropolitano Niguarda and Università Vita-Salute San Raffaele; both in Milan, Italy
Paolo G Camici, Professor
study chair · Università Vita-Salute San Raffaele and Hospital, Milan, Italy

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Iodixanol · Contrast agent BR1

Start the discussion